EMERYVILLE, Calif.,
Sept. 9, 2021 /PRNewswire/
-- Dynavax Technologies Corporation (Nasdaq: DVAX), a
biopharmaceutical company focused on developing and commercializing
vaccines, today announced that Ryan
Spencer, Chief Executive Officer, will present at the H.C.
Wainwright 23rd Annual Global Investment Conference being held
virtually September 13-15, 2021.
The on demand presentation will be available, beginning
Monday, September 13, 2021 at
7:00 a.m. E.T. and may be accessed
through the "Events & Presentations" page on the "Investors"
section of the Company's website at
http://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial stage
biopharmaceutical company developing and commercializing novel
vaccines. The Company's first commercial product, HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the
U.S. and Europe for prevention of
infection caused by all known subtypes of hepatitis B virus in
adults age 18 years and older. Dynavax is also advancing CpG 1018
adjuvant as a premier vaccine adjuvant through research
collaborations and partnerships. Current collaborations are focused
on adjuvanted vaccines for COVID-19, pertussis and universal
influenza. For more information, visit www.dynavax.com and
follow the company on LinkedIn.
Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301372861.html
SOURCE Dynavax Technologies